Patents Assigned to Sphingotec GmbH
-
Publication number: 20180128838Abstract: The present invention relates to means and methods suitable for risk prediction of chronic kidney disease (CKD) using Pro-Enkephalin or fragments thereof as biomarker. The risk prediction methods of the invention are intended for healthy subjects and for subjects suffering from diseases such as hypertension, cardiovascular diseases and events, diabetes, metabolic syndrome, obesity, or autoimmune diseases. Subject matter of the invention is also a method of predicting the worsening or improvement of kidney function or dysfunction in healthy and diseased individuals.Type: ApplicationFiled: April 21, 2016Publication date: May 10, 2018Applicant: sphingotec GmbHInventors: Andreas BERGMANN, Olle MELANDER
-
Publication number: 20170307618Abstract: Subject matter of the present invention is a method for predicting the risk of getting cancer in a female subject that does not suffer from cancer or alternatively diagnosing cancer in a female subject comprising: determining the level of Pro-Enkephalin or fragments thereof including Leu-Enkephalin and Met-Enkephalin of at least 5 amino acids in a bodily fluid obtained from said female subject; and correlating said level of Pro-Enkephalin or fragments thereof with a risk for getting cancer, wherein a reduced level is predictive for an enhanced risk of getting cancer or alternatively diagnosing cancer wherein an reduced level is correlated with the diagnosis of cancer.Type: ApplicationFiled: July 5, 2017Publication date: October 26, 2017Applicant: SPHINGOTEC GMBHInventors: Andreas BERGMANN, Olle MELANDER
-
Publication number: 20170261522Abstract: A method for (a) diagnosing or monitoring kidney function in subject or (b) diagnosing kidney dysfunction in a subject or (c) predicting or monitoring the risk of an adverse events in a diseased subject or (d) predicting or monitoring the success of a therapy or intervention comprising determining the level of Pro-Enkephalin (PENK) or fragments thereof of at least 5 amino acids in a bodily fluid obtained from said subject; and correlating said level of Pro-Enkephalin or fragments thereof with (a) kidney function in a subject or (b) kidney dysfunction in said subject or (c) enhanced risk of adverse events or (d) success of a therapy or intervention in a diseased subject.Type: ApplicationFiled: May 9, 2017Publication date: September 14, 2017Applicant: SPHINGOTEC GMBHInventor: Andreas BERGMANN
-
Publication number: 20170234889Abstract: A method of determining whether a subject has a vascular risk that can be reduced by blood pressure lowering therapy with antihypertensive drugs (e.g. Angiotensin converting enzyme inhibitor (ACE inhibitor), Angiotensin Receptor Blocker (ARB), Beta-Adrenoreceptor Blocker (Beta-blocker) and/or statins) by determining the level of hGH, and/or its isoforms in a blood sample of said subject and comparing the determined level of hGH, and/or its isoforms in said blood sample with a pre-determined threshold.Type: ApplicationFiled: October 1, 2015Publication date: August 17, 2017Applicant: Sphingotec GmbHInventors: Andreas BERGMANN, Olle MELANDER, Leong NG
-
Patent number: 9702876Abstract: Subject matter of the present invention is a method for predicting the risk of getting cancer in a female subject that does not suffer from cancer or alternatively diagnosing cancer in a female subject comprising: determining the level of Pro-Enkephalin or fragments thereof including Leu-Enkephalin and Met-Enkephalin of at least 5 amino acids in a bodily fluid obtained from said female subject; and correlating said level of Pro-Enkephalin or fragments thereof with a risk for getting cancer, wherein a reduced level is predictive for an enhanced risk of getting cancer or alternatively diagnosing cancer wherein an reduced level is correlated with the diagnosis of cancer.Type: GrantFiled: October 1, 2013Date of Patent: July 11, 2017Assignee: SPHINGOTEC GMBHInventors: Andreas Bergmann, Olle Melander
-
Patent number: 9664695Abstract: A method for (a) diagnosing or monitoring kidney function in subject or (b) diagnosing kidney dysfunction in a subject or (c) predicting or monitoring the risk of an adverse events in a diseased subject or (d) predicting or monitoring the success of a therapy or intervention comprising determining the level of Pro-Enkephalin (PENK) or fragments thereof of at least 5 amino acids in a bodily fluid obtained from said subject; and correlating said level of Pro-Enkephalin or fragments thereof with (a) kidney function in a subject or (b) kidney dysfunction in said subject or (c) enhanced risk of adverse events or (d) success of a therapy or intervention in a diseased subject.Type: GrantFiled: October 1, 2013Date of Patent: May 30, 2017Assignee: Sphingotec GmbHInventor: Andreas Bergmann
-
Publication number: 20170052203Abstract: Subject of the present invention is an in vitro method for therapy follow-up in septic patients wherein the concentration of mature ADM 1-52 and/or mature ADM 1-52-Gly in a sample of bodily fluid of said septic patient is determined using an assay comprising two binders that bind to two different regions within the region of mature adrenomedullin and/or adrenomedullin-Gly that is aminoacid 21-52-amid SEQ. ID No. 1 or aminoacid 21-52-Gly SEQ ID No. 2 wherein each of said regions comprises at least 4 or 5 amino acids. Subject of the present invention are further assays and calibration methods.Type: ApplicationFiled: November 7, 2016Publication date: February 23, 2017Applicant: SPHINGOTEC GMBHInventor: Andreas BERGMANN
-
Publication number: 20170010286Abstract: Subject matter of the present invention is an in vitro method for identifying a subject in need of administration of fluid resuscitation or a vasopressor comprising the following steps: Determining the level of proADM and/or fragments thereof having at least 6 amino acids in a bodily fluid of said subject Correlating said level with the need of said patient for fluid resuscitation or administration of a vasopressor wherein said patient is identified as having such a need if the level of proADM and/or fragments thereof having at least 6 amino acids in the bodily fluid of said subject is above a threshold.Type: ApplicationFiled: March 19, 2014Publication date: January 12, 2017Applicant: SphingoTec GmbHInventor: Andreas BERGMANN
-
Patent number: 9535060Abstract: Subject of the present invention is an in vitro method for therapy follow-up in septic patients wherein the concentration of mature ADM 1-52 and/or mature ADM 1-52-Gly in a sample of bodily fluid of said septic patient is determined using an assay comprising two binders that bind to two different regions within the region of mature adrenomedullin and/or adrenomedullin-Gly that is aminoacid 21-52-amid SEQ ID No. 1 or aminoacid 21-52-Gly SEQ ID No. 2 wherein each of said regions comprises at least 4 or 5 amino acids. Subject of the present invention are further assays and calibration methods.Type: GrantFiled: November 16, 2012Date of Patent: January 3, 2017Assignee: SPHINGOTEC GMBHInventor: Andreas Bergmann
-
Publication number: 20160252526Abstract: Disclosed is a method for predicting the risk of getting a major adverse cardiac event or death in a subject that has suffered an acute myocardial infarction containing determining the level of Protachykinin or fragments thereof of at least 5 amino acids in a bodily fluid obtained from the subject; and correlating the level of Protachykininor fragments thereof with the a risk for getting a major adverse cardiac event or death, wherein an elevated level is predictive for an enhanced risk of getting a major adverse cardiac event or death.Type: ApplicationFiled: September 30, 2014Publication date: September 1, 2016Applicant: sphingotec GmbHInventors: Andreas BERGMANN, Leong NG
-
Publication number: 20160097781Abstract: Subject matter of the present invention is a method for stratifying a female subject for hormone replacement therapy wherein the level of Pro-Neurotensin or fragments thereof is determined and the level of Pro-Enkephalin or fragments thereof is determined.Type: ApplicationFiled: October 1, 2015Publication date: April 7, 2016Applicant: SPHINGOTEC GMBHInventors: Andreas BERGMANN, Olle MELANDER
-
Publication number: 20150346222Abstract: Subject matter of the present invention is a method for predicting the cardiovascular risk or the total mortality risk in a subject comprising: determining the fasting level of growth hormone (hGH), and/or its isoforms in a bodily fluid obtained from said subject; and correlating said fasting level of growth hormone (hGH), and/or its isoforms with a cardiovascular risk or the total mortality risk, wherein an enhanced level is predictive for an enhanced risk.Type: ApplicationFiled: January 7, 2014Publication date: December 3, 2015Applicant: SPHINGOTEC GMBHInventor: Andreas BERGMANN
-
Publication number: 20150346207Abstract: Subject matter of the present invention is a method for predicting the risk of getting cancer in a subject that does not suffer from cancer or alternatively diagnosing cancer in a subject comprising: determining the level of Pro-Tachykinin, its splice variants or fragments thereof including Substance P and Neurokinin of at least 5 amino acids in a bodily fluid obtained from said subject; and correlating said level of Pro-Tachykinin, its splice variants or fragments thereof with a risk for getting cancer, wherein a reduced level is predictive for an enhanced risk of getting cancer or alternatively diagnosing cancer wherein an reduced level is correlated with the diagnosis of cancer.Type: ApplicationFiled: January 7, 2014Publication date: December 3, 2015Applicant: SphingoTec GmbHInventor: Andreas BERGMANN
-
Patent number: 9188591Abstract: The present invention relates to the use of protachykinin and/or fragments thereof that can be isolated from body fluids, tissues or other biological samples and therefore, serves as a marker peptide for medical diagnosis of diseases/disorders of the central nervous system, including Alzheimer's disease, Parkinson's disease, depression and/or conditions of pain, neurological, endocrinological, cerebral, muscular, local, systemic, chronic, inflammatory diseases, infectious diseases comprising bacterial and viral infections, meningitis, sepsis, Crohn's disease, colitis ulcerosa, sickle cell anemia, ischemia, amyotrophic lateral sclerosis, arthritis comprising rheumatoid arthritis, bronchitis, hyperalgesia, asthma, intoxication comprising bacterial intoxication, immunological disorders, poly/-trauma comprising cranio-cerebral trauma, tumors/cancer, stroke, stress, atopis dermatitis, HIV, Huntington's disease, burns, schizophrenia, Hirschsprung's disease, allergies, familial dysautononmia (Riley Day syndrome), heType: GrantFiled: November 4, 2010Date of Patent: November 17, 2015Assignee: SPHINGOTEC GMBHInventors: Andreas Bergmann, Andrea Ernst
-
Publication number: 20150268240Abstract: Subject matter of the present invention is a method for predicting the risk of getting cancer in a female subject that does not suffer from cancer or alternatively diagnosing cancer in a female subject comprising: determining the level of Pro-Enkephalin or fragments thereof including Leu-Enkephalin and Met-Enkephalin of at least 5 amino acids in a bodily fluid obtained from said female subject; and correlating said level of Pro-Enkephalin or fragments thereof with a risk for getting cancer, wherein a reduced level is predictive for an enhanced risk of getting cancer or alternatively diagnosing cancer wherein an reduced level is correlated with the diagnosis of cancer.Type: ApplicationFiled: October 1, 2013Publication date: September 24, 2015Applicant: SPHINGOTEC GMBHInventors: Andreas Bergmann, Olle Melander
-
Publication number: 20150260732Abstract: A method for (a) diagnosing or monitoring kidney function in subject or (b) diagnosing kidney dysfunction in a subject or (c) predicting or monitoring the risk of an adverse events in a diseased subject or (d) predicting or monitoring the success of a therapy or intervention comprising determining the level of Pro-Enkephalin (PENK) or fragments thereof of at least 5 amino acids in a bodily fluid obtained from said subject; and correlating said level of Pro-Enkephalin or fragments thereof with (a) kidney function in a subject or (b) kidney dysfunction in said subject or (c) enhanced risk of adverse events or (d) success of a therapy or intervention in a diseased subject.Type: ApplicationFiled: October 1, 2013Publication date: September 17, 2015Applicant: SPHINGOTEC GMBHInventor: Andreas Bergmann
-
Patent number: 8916388Abstract: In vitro multiparameter method for the diagnosis and early diagnosis, for determination of the severity and for assessing the course and prognosis of neurodegenerative disorders, in which the concentrations of at least two different vasotropic peptides are determined in a biological fluid from a person suffering from subjective or objectively detectable cognitive impairments, the resulting person-specific measurements are combined computationally to give a person-specific complex reference value, and conclusions are drawn concerning the presence of a neurodegenerative disorder in the person on the basis of the person-specific complex reference value found.Type: GrantFiled: June 15, 2007Date of Patent: December 23, 2014Assignee: Sphingotec GmbHInventors: Andreas Bergmann, Andrea Ernst, Harald Hampel
-
Publication number: 20140322824Abstract: Subject of the present invention is an in vitro method for therapy follow-up in septic patients wherein the concentration of mature ADM 1-52 and/or mature ADM 1-52-Gly in a sample of bodily fluid of said septic patient is determined using an assay comprising two binders that bind to two different regions within the region of mature adrenomedullin and/or adrenomedullin-Gly that is aminoacid 21-52-amid SEQ ID No. 1 or aminoacid 21-52-Gly SEQ ID No. 2 wherein each of said regions comprises at least 4 or 5 amino acids. Subject of the present invention are further assays and calibration methods.Type: ApplicationFiled: November 16, 2012Publication date: October 30, 2014Applicant: SPHINGOTEC GMBHInventor: Andreas Bergmann
-
Patent number: 8637256Abstract: The invention relates to an immunodiagnostic method for determining the release of neurotensin into the circulation of mammals based on the selective determination of an immunoreactivity of the N-terminal portion of a mammal proneurotensin (PNT immunoreactivity) in a serum or plasma sample of a mammal; this immunoreactivity is not neurotensin or neuromedin immunoreactivity.Type: GrantFiled: January 25, 2006Date of Patent: January 28, 2014Assignee: Sphingotec GmbHInventor: Andrea Ernst
-
Publication number: 20120231475Abstract: The invention relates to an immunodiagnostic determination method for determining the release of neurotensin into the circulation of mammals during which an immunoreactivity of the N-terminal portion of a mammal proneurotensin (PNT immunoreactivity) is selectively determined in a serum sample or plasma sample of a test mammal, this immunoreactivity not being a neurotensin or neuromedin immunoreactivity.Type: ApplicationFiled: February 22, 2012Publication date: September 13, 2012Applicant: SPHINGOTEC GMBHInventor: Andrea ERNST